Department of Internal Medicine, Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Republic of Korea.
BIOINFRA Life Science Inc., 7th Floor, 49, Daehak-ro, Jongno-gu, Seoul, Republic of Korea.
Clin Chim Acta. 2021 May;516:169-178. doi: 10.1016/j.cca.2021.02.002. Epub 2021 Feb 10.
The ultimate goal of cancer screening is to diagnose invasive cancers early, while they are still curable. We aimed to validate the diagnostic value of blood-derived protein biomarkers that we developed for six common cancer in Korea.
We have discovered 12 protein biomarkers that are useful in differentiating cancer patients from healthy controls using two-dimensional gel electrophoresis (2-DE), surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), and literature review. Cancer patients (stomach, colon, liver, lung, breast, and prostate) and control subjects were collected and tested data sets were used to generate predictive models that identify risk scores for each cancer. The validation study was done in serum samples of an independent patient cohort Receiver operating characteristic (ROC) analyses were conducted to evaluate the diagnostic performance of the biomarkercombinations.
The AUCs of the model in the test set were 0.971, 0.960, 0.969, 0.942, 0.834, and 0.985 for stomach, colon, liver, lung, breast, and prostate cancer, respectively.
Combining multiple tumor and systemic inflammatory biomarkers proved to be a valid strategy in the diagnosis of six common cancers in Korea. Further validation of appropriate screening populations through large-scale clinical trials are warranted.
癌症筛查的最终目标是早期诊断侵袭性癌症，使其仍然可以治愈。我们旨在验证我们为韩国六种常见癌症开发的血液来源蛋白生物标志物的诊断价值。
我们使用二维凝胶电泳（2-DE）、表面增强激光解吸/电离飞行时间质谱（SELDI-TOF-MS）和文献综述发现了 12 种蛋白生物标志物，可用于区分癌症患者和健康对照者。收集了癌症患者（胃癌、结肠癌、肝癌、肺癌、乳腺癌和前列腺癌）和对照组，并测试了数据集，以生成可识别每种癌症风险评分的预测模型。验证研究在独立患者队列的血清样本中进行，进行了接收器操作特性（ROC）分析以评估生物标志物组合的诊断性能。
在测试集中，该模型对胃癌、结肠癌、肝癌、肺癌、乳腺癌和前列腺癌的 AUC 分别为 0.971、0.960、0.969、0.942、0.834 和 0.985。
组合多种肿瘤和系统性炎症生物标志物被证明是韩国六种常见癌症诊断的有效策略。需要通过大规模临床试验进一步验证合适的筛查人群。
